Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Etubics›
Website
AddedFeb 15, 2024
UpdatedJun 18, 2026
Etubics

Etubics

Series A

Seattle-based Etubics Corp. develops safer, efficient immunotherapies and vaccines using patented technology.

HQ
Seattle, WA, US
Founded
2003
Loading
Overview
Compare
Fundraising
Employees
Website

Etubics - Website

An index of every page on etubics.com, by section.

11 pages across 6 sections · Updated Jul 19, 2026·

Homepage

Etubics's front door: current positioning and top-line messaging.

immunitybio.com

Careers

Open roles and how Etubics recruits, straight from the source.

immunitybio.com/careers

ComparisonImmunitybio Completes Enrollment in Pivotal Randomized Trial Evaluating Anktiva Plus Bcg Versus Bcg Alone in Bcg Naive Non Muscle Invasive Bladder Cancer Carcinoma in Situ

6 comparison pages published by Etubics.

  • Immunitybio Completes Enrollment in Pivotal Randomized Trial Evaluating Anktiva Plus Bcg Versus Bcg Alone in Bcg Naive Non Muscle Invasive Bladder Cancer Carcinoma in Situoff-site
  • Immunitybio Confirms Statistical Power in Pivotal Randomized Bcg Naive Nmibc Trial to Detect Clinically Meaningful Differences Between Anktiva Plus Bcg Versus Bcg Alone Supplemental Bla Submissoff-site
  • Immunitybio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of Nai Bcg Versus Nadofaragene and Tar 200 at Aua 2026off-site
  • Immunitybio Presents Health Economic Analysis at Ispor 2026 Showing Anktiva Plus Bcg Delivers Lower Cost per Sustained Complete Response Versus Tar 200 in Bcg Unresponsive Nmibc Cisoff-site
  • P3 18 53 Phase 3 Clinical Trial Resq201a of N 803 Nai Tislelizumab and Docetaxel vs Docetaxel Monotherapy for Advanced Nsclc Resistant to Ici Therapyoff-site
  • P3 18 52 Phase 3 Trial Resq201a of Nai Plus Tislelizumab and Docetaxel vs Docetaxel Monotherapy for Advanced or Metastatic Nsclc Resistant to Ici Therapyoff-site

About

Company story, mission, and background as Etubics tells it.

immunitybio.com/about

Contact

Sales, support, and partnership channels for reaching Etubics directly.

immunitybio.com/contact

PrivacyPrivacy Policy

How Etubics collects, uses, and safeguards data: the canonical policy set.

immunitybio.com/privacy-policy